

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/052,758	01/18/2002	Nicholas deBeer	TSNMNP00100	1588
40518 7590 11/16/2007 LEVINE BAGADE HAN LLP 2483 EAST BAYSHORE ROAD, SUITE 100			EXAMINER	
			SCHILLINGER, ANN M	
PALO ALTO, CA 94303			ART UNIT	PAPER NUMBER
			. 3774	
		·		
			MAIL DATE	DELIVERY MODE
			11/16/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/052,758	DEBEER ET AL.
Office Action Summary	Examiner	Art Unit
	Ann Schillinger	3774
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet w	vith the correspondence address
A SHORTENED STATUTORY PERIOD FOR REF WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory peri Failure to reply within the set or extended period for reply will, by stat Any reply received by the Office later than three months after the ma earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUN 1.136(a). In no event, however, may a od will apply and will expire SIX (6) MO tute, cause the application to become A	ICATION. I reply be timely filed INTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 13	3 August 2007.	
, , , , , , , , , , , , , , , , , , , ,	his action is non-final.	
3) Since this application is in condition for allow closed in accordance with the practice unde	•	·
Disposition of Claims		
4)⊠ Claim(s) 3,4,6,8,9,13,14,16,18,19,21,22 and 4a) Of the above claim(s) 3,4,6,8,9,13,14,16 5)□ Claim(s) is/are allowed. 6)⊠ Claim(s) 24-37 is/are rejected. 7)□ Claim(s) is/are objected to. 8)□ Claim(s) are subject to restriction and	<u>,18,19,21,22 and 38</u> is/are v	
Application Papers		
9) The specification is objected to by the Exam	iner.	
10) The drawing(s) filed on is/are: a) a	accepted or b)□ objected to	by the Examiner.
Applicant may not request that any objection to t		
Replacement drawing sheet(s) including the corr	' '	
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for forei a) All b) Some * c) None of:	ign priority under 35 U.S.C.	§ 119(a)-(d) or (f).
1. Certified copies of the priority docume		
2. Certified copies of the priority docume		
3. Copies of the certified copies of the p	•	n received in this National Stage
application from the International Bure	, , , , , , , , , , , , , , , , , , , ,	t raceived
* See the attached detailed Office action for a l	ist of the certified cobies no	n receiveu.
Attachment(s)		
1) Notice of References Cited (PTO-892)		Summary (PTO-413)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) 		o(s)/Mail Date Informal Patent Application
Paper No(s)/Mail Date	6) Other:	

Application/Control Number: 10/052,758

Art Unit: 3774

DETAILED ACTION

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 24-29 and 31-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Huebsch et al. (US Pat. No. 5,853,422) in view of Shaw et al. (US Pat. No. 6,080,182). Huebsch et al. discloses a catheter delivered septal defect occluder comprising: a tubular frame having parallel slits (col. 3, lines 39-44), made of NITINOL, a nickel-titanium shape memory alloy, (col. 3, lines 64- col. 4, line 1), with circular biodegradable sheets over each end of the frame (col. 7, lines 44-48), the frames forming umbrellas that bend towards the midpoint of the frame (e.g. Figs. 23 and 24). However, Huebsch et al. does not disclose a self-expanding device.

Shaw et al. teaches a device for sealing septal defect that is self-expanding in columns 3, 5, and 6 for the purpose of facilitating the insertion of the device.

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to make the device self-expanding in order to facilitate the insertion of the device.

Claims 30 and 37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Huebsch et al. in view of Shaw et al, as above, in further view of Goldstein et al. (US Pat. No. 6,143,037). Huebsch et al. and Shaw et al. disclose the claimed septal defect occluder, however,

Application/Control Number: 10/052,758

Art Unit: 3774

they fail to disclose the occluder having a galactide and lactide copolymer member covering at least a portion of the umbrella or disc shaped halves.

Goldstein et al. teaches a septal defect occluder (col. 31, lines 26-47) having a member (col. 6, lines 33-41) made of a copolymer of glycolic acid and lactic acid (col. 15, lines 37-40) which is useful for targeted local delivery of pharmaceutical agents at a site of medical intervention (col. 1, lines 8-11).

It would have been obvious to one of ordinary skill in the art to combine the f teaching of a member made of a copolymer of glycolic acid and lactic acid, as taught by Goldstein et al., to a septal defect occluder as per Huebsch et al., for targeted local delivery of pharmaceutical agents at a site of medical intervention. Please Note: a glycolic acid and lactic acid copolymer is a galactide-lactide copolymer as admitted by the Applicant (p 11, lines 7-13).

Response to Arguments

Applicant's arguments with respect to claims 24-37 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ann Schillinger whose telephone number is (571) 272-6652. The examiner can normally be reached on Mon. thru Fri. 9 a.m. to 4 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on (571) 272-4754. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/052,758 Page 4

Art Unit: 3774

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Ann Schillinger November 2, 2007

ALVIN J. STEWART PRIMARY EXAMINER